Crmd stock price forecast investors monitor FDA timelines closely

Investors monitor FDA timelines closely, given their outsized influence on medtech valuations. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. The earnings estimate of $0.15 per share for the current quarter represents a change of +160% from the number reported a year ago. New revisions to "CRMD stock price forecast" incorporate technical strength, with the stock holding above key moving averages for 15 consecutive sessions. If momentum continues, analysts see a 10% upside in Q